LAPL, based in Ancaster, Ontario, was established in 2001 as a biotech and pharmaceutical development and analysis enterprise.

LAPL’s labs are fully equipped with modern analytical and molecular biology instruments. LAPL has rich experience in isolation, identification and characterization of impurities in active pharmaceutical ingredients, establishment of impurity profiles including identification and structure elucidation, and quantitative determination of impurities and degradation products in bulk drug materials and pharmaceutical formulations.

LAPL is familiar with the US Pharmacopeia, British Pharmacopeia, European Pharmacopeia and Chinese Pharmacopeia, analytical method development and validation, current Good Manufacturing Practices (cGMP), FDA and Health Canada compliance, and pharmaceutical API quality control.  LAPL's expertise can assist customers in selecting from complex materials the proper compounds for analysis or pharmacological investigation and in establishing methods to carry out such studies.

LAPL has been using recombinant DNA technology for many years to investigate the mechanisms of antibiotic resistance, generate new higher-yielding antibiotic-producing strains and develop new medically-valuable antimicrobial drugs.

LAPL personnel have many years of experience in the areas of laboratory management, project development, equipment calibration, pharmaceutical product development, analytical R&D and Quality Control, regulatory requirements, molecular biology, fermentation, etc.  Consultation services are available in these areas.